Primary
Hyperoxaluria is a condition characterized by kidney and bladder stones that
are recurrent. This condition further advances to end stage renal disease
(ESRD), which is life – threatening since it prevents kidneys from filtering
the fluids essential for the body from the waste products effectively.
This
condition is a result of the overproduction of oxalate. Oxalate is excreted as
a waste through urine after it gets filtered through the kidneys. This leads to
abnormally high level of oxalate in urine which is why it is called as
hyperoxaluria. When excreted, the oxalate can sometimes combine with calcium to
form calcium oxalate, which is the main component of kidney and bladder
stones. If these calcium oxalate
compounds are deposited, it can lead to damage of kidneys or other organs as
well. This will ultimately lead to blood in the urine and other urinary, kidney
infections. This whole process weakens the kidneys and overtime, they lose the
ability to excrete as much oxalate as they receive. The excess oxalate results
in blood rise and these substances get deposited in tissues throughout the
body, especially in bones and blood vessels. Bones are weakened and this leads
to fractures.
Based
on their severity and genetic reasons, primary hyperoxaluria are of three
types. In Type 1, kidney stones appear right from childhood to early childhood.
In Type 2, it develops later in life. In Type 3, affected individuals develop
kidney stones in early childhood, but additional signs and symptoms are unclear
since few cases have been reported so far. This condition is inherited in an
autosomal recessive pattern, where both copies of gene in each cell have
mutations. In cases caused genetically, the parents of the individual each
carry one copy of the mutated gene but do not really show signs or symptoms of
the condition.
Pipeline
Review is an online portal that provides R&D new and online shop for
reports about research & development in the biopharmaceutical industry. Ken
Research’s Primary
Hyperoxaluria-Pipeline Review, H2 2018 gives a snapshot of the
therapeutic landscape of the disorder. The report covers therapeutic reviews
based on their companies and research institutions based on their information
derived from industry- specific sources. It provides descriptive drug profiles
for the pipeline products which comprise product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities. The companies involved in therapeutic development in
Primary Hyperoxaluria are Allena Pharmaceuticals Inc, Alnylam Pharmaceuticals
Inc, Dicerna Pharmaceuticals Inc, Intellia Therapeutics Inc and OxThera AB. The
report will help in procuring important information on competitors and their
analysis to formulate R&D strategies to develop tactical initiatives in the
target demographic.
For more information, click on the
link below:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91
9015378249